Caricamento...
Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact
BACKGROUND: Meningococcal disease remains an important cause of morbidity and mortality worldwide. The first broadly effective vaccine against group B disease (which causes considerable meningococcal disease in Europe, the Americas and Australasia) was licensed in the EU in January 2013; our objecti...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Elsevier Science
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3743045/ https://ncbi.nlm.nih.gov/pubmed/23566946 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2013.03.034 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|